AZD9291 in Combination With Ascending Doses of Novel Therapeutics

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

DRUG: Part A - AZD9291 in combination with AZD6094
DRUG: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
DRUG: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
DRUG: Part A - AZD9291 in combination with intermittent selumetinib
DRUG: Part A - AZD9291 in combination with MEDI4736
DRUG: Part B - AZD9291 in combination with AZD6094
DRUG: Part B - AZD9291 in combination with selumetinib
DRUG: Part B - AZD9291 in combination with MEDI4736
DRUG: Part C - AZD6094 monotherapy (Japan only)
DRUG: Part C - AZD9291 in combination with AZD6094 (Japan only)
DRUG: Part D - AZD9291 in combination with AZD6094

AstraZeneca